Article

Steven Pearson, MD, Addresses Formulary Decision Making

Almost all pharmacy and therapeutic committees have a unique process for evidence-based formulary decision making, said Steven Pearson, MD, founder & president, Institute for Clinical and Economic Review.

Almost all pharmacy and therapeutic committees have a unique process for evidence-based formulary decision making, said Steven Pearson, MD, founder & president, Institute for Clinical and Economic Review. “Evidence is an anchor and obviously the strongest part of the foundation of evidence-based decision making, but it’s just a piece of a larger whole,” said Dr Pearson. Dr Pearson also explains the “level of certainty” when determining the strength of evidence behind research. When making formulary decisions it is important to determine the net health benefit and the level of certainty in that benefit. “Overall, it is helpful to think, is the level of certainty in your evidence high, moderate, or low? Because according to that I think it really flows through into the way into you would think about using that evidence in a formulary decision,” said Dr Pearson.

Related Videos
Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi
RAvin Ratan, MD, MEd, MD Anderson
Melissa B. Jones, MD, staff nurse psychiatrist, Michael E. DeBakey VA Medical Center; assistant professor of psychiatry, Baylor College of Medicine
Ali Khawar
Monica Kraft, MD, ATSF.
Michael Arzt, MD.
Julie Linton, MD, FAAP.
Jan Hedner, MD, PhD.
Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council
Related Content
CH LogoCenter for Biosimilars Logo